Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma

Trial Profile

Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma

Suspended
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Adult T-cell leukaemia-lymphoma; HTLV-I infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Dec 2017 Status changed from recruiting to suspended due to scheduled interim monitoring
    • 07 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 23 Mar 2016 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top